Review Article
Ravi Velaga and Masakazu Toi, ‘Advances in Molecular Medicine for Breast Cancer Practice: A Narrative Review’ (2022) 7 Annals of Breast Surgery 38.
Students exploring complex scientific concepts and research-based topics can access academic resources through our best assignment help Australia platform.
Serial equity in breast cancer Molecular Medicine
The past two years have also experienced evolution in the molecular therapy of breast cancers. Genomic profiling, discovery of biomarkers and rational drug design allow clinicians to gradually tailor therapy to specific tumour subtypes. Recent narrative review by Velaga and colleagues (REV) summarised the progress made in biomarker-based strategy, immunotherapy and targeted molecular therapies. Particularly, the review determines how current oncology models are revolutionising the practise of breast cancer by integrating the diagnostic testing such as gene expression of diverse signatures and circulating cancer biomarkers alongside improvement in therapeutic modalities. It is founded on this, that current Australian research on epigenetic reprogramming (CIA) and chromatin remodelling (CIA) demonstrates that molecular medicine in future approaches will assist in overcoming breast cancer resistance and heterogeneity.
Biomolecular Characterisation and Preparation of Biomarkers.
Precision medicine of breast cancer is centered upon the implementation of molecular profiling as one of the strategies to subdivide patients into actionable, clinical groups, i.e. Oncotype DX and PAM50 are examples of more frequently used genomic gene expression signatures to determine cancer risk recurrence and response to chemotherapy in clinical practice (Velaga et al., 2023 REV). Similarly, overviews of minuscule invasive instruments in the early identification and following up of conditions incorporate a liquid biopsy, which examines destroyed tumour DNA (ctDNA) or circulated tumour cells. These recommendations are consistent with those of Australian research that suggests a stable potential of DNA methylation to endocrine-resistant cancers (CIA) that support aberrant loops of the enhancers and promoters that can be destabilised under the influence and influence of demethylation agents to revitalise tumour suppressor activities.
The other suggestion about the importance of applying the proteomic and transcriptomic biomarkers in clinical practice is that they should be implemented in aggressive subtypes such as the triple-negative breast cancer (TNBC). In this regard, more recent Australian experiments involving CRISPR/dCas9-mediated epigenetic editing have validated the claim that mesenchymal TNBC cells can be reprogrammed to epitheliocytes (CIA).
Understanding biomarkers, molecular profiling and targeted therapies is an important part of Medical Science Assignment Help, particularly when studying modern cancer treatments.
Innovative Therapy and M1.
The second important aspect of Velaga et al. (2023 REV) is the enhanced role of immunotherapy. Pembrolizumab, which is an immune checkpoint inhibitor, was also proven effective in TNBC but is effective on one group of patients only or on another. The review identifies optimisation of predictive biomarkers to identify responders and minimize immune-related toxicity. The study area is particularly relevant to the Australian research setting in which tumour immunogenicity can be enhanced through increased molecular processes intended to control epigenetic conditions. One example is the increase in expression of endogenous retroviral factors by use of DNA demethylation treatment (CIA), which stimulates innate immune response and this can be used with checkpoint blockade.
In the meantime, personalised therapy remains dependent on a given molecular therapy. Hormone receptor-positive disease CDK4/6 inhibitors and HER 2 targeted medicine trastuzumab and pertuzumab are examples of efficacious uses of rational drug design (MT). As an outcome, it is however common that resistance mechanisms often develop and are then actively, in response, induced by epigenomic reprogramming or tumour plasticity. The theoretical basis of resistance against the Australian CRISPR/dCas9 reprogramming study (CIA) is to directly change the changes of state at the cellular level rather than at the level of individual molecules. Such strategies and use of immunotherapy can be regarded as a new aspect of molecular medicine.
Winning the Battle against Resistance through Epigenetic Therapies.
Supposedly, the heterogeneity and resistance to treatment of breast cancer are the most critical barriers to its permanent control (Velaga et al., 2023 REV). One of the recent strategies that may be employed in order to address such obstacles is the epigenetic therapies that are able to take action on the dynamism of the regulatory structure of the genome. The claim that chromatin reprogramming permits ER+ breast cancer with an endocrine resistance to be sensitised in phase 2 decitabine (CIA) Australian phase 2 trial directly supports this claim. The pathological enhancer-promoter future interactions of the treatment responsiveness can also be reinstated through the assistance of the epigenetic agents.
The general literature review which is quickly gaining enlightenment on the plasticity of afflicted breast cancer cells is well relatable to these results. The changes in the epigenetics are reversible or re-patternable and hence, unlike mutation, they potentially can be reversed and hence, the development of a means to reverse these changes may be a remedy to the issue of therapeutic sensitivity. This connotes that synergistic effects should be achieved in a combination of epigenetic drugs and targeted therapeutic (e.g. HER2 or PARP). Indeed, Velaga et al. (2023 REV) volunteer to imagine that in the future of molecular medicine, genetic, epigenetic, and immunological images should be combined to be utilised.
Clinical Practice Translation.
However, the situation regarding clinical benefit translation of molecular medicine discovery remains complex as per the perspective of attaining clinical benefit. Velaga et al. (2023 REV) recognize it needs to be conducted on a large scale, to validate in the real world, and be integrated into health systems to facilitate equitable access. This requires the normalisation at the Australian level of the incidence of breast cancer by costly molecular diagnostics and targeted therapy. The government (country) subsidising implosive research such as the one described in the former section (CIA) is impossible in ensuring that inventions are accessible and to the patients in the most efficient manner possible.
Interestingly, as Velaga et al. (2023 REV) point out, further clinical practice will be confined not only to finding new therapies, but it is also the application of multi-omic data in the decision-making process. Synthetic epigenetic reprogramming or epigenetic therapy by Australian researchers demonstrate that it is not only possible to develop local answers to global problems, but also to apply local solutions to local problems in the Australian healthcare system.
Conclusion
The REV by Velaga et al. (2023) review is a general overview of the revision of the concept of molecular medicine in breast cancer medication. Together with new Australian approaches to epigenetic reprogramming (CIA) and chromatin remodelling (CIA), it is evident that the sector is being impelled towards curing treatments not merely on molecular lesions but also on restructuring cell states and regulatory structures.
Reference List
- CIA Primary Research Articles
- (Waryah, C., Cursons, J., Foroutan, M., Pflueger, C., Wang, E., Molania, R., Woodward, E., Sorolla, A., Wallis, C., Moses, C., Glas, I., Magalhães, L., Thompson, E. W., Fearnley, L. G., Chaffer, C. L., Davis, M., Papenfuss, A. T., Redfern, A., Lister, R., . . . Blancafort, P. (2023). Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer. Advanced Science, 10(22), 2301802. https://doi.org/10.1002/advs.202301802
- (Stirzaker, C., Portman, N., Campbell, E., Chia, K., Du, Q., Nair, S. S., Yong, A., Wilkinson, A., Clifton, S., Milioli, H. H., Alexandrou, S., Caldon, C. E., Song, J., Khoury, A., Meyer, B., Chen, W., Pidsley, R., Qu, W., Gee, J. M., . . . Clark, S. J. (2024). The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer. Nature Structural & Molecular Biology, 31(3), 498-512. https://doi.org/10.1038/s41594-023-01181-7 )
- Review Article
- (Ravi Velaga and Masakazu Toi, ‘Advances in Molecular Medicine for Breast Cancer Practice: A Narrative Review’ (2022) 7 Annals of Breast Surgery 38. https://abs.amegroups.org/article/view/7614/html?utm_source )
- REV (Review Articles)
- Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L., Huang, L., Liu, C., Shao, Z., & Yu, K. (2025). Breast cancer: Pathogenesis and treatments. Signal Transduction and Targeted Therapy, 10(1), 1-33. https://doi.org/10.1038/s41392-024-02108-4
- Ran, R., Tan, J., & Liu, H. (2025). Immunotherapy in breast cancer: current landscape and emerging strategies. Experimental Hematology & Oncology, 14(1), Article 66–67. https://ehoonline.biomedcentral.com/articles/10.1186/s40164-025-00667-y
- Kim, N., & Lukong, K. E. (2025). Treating ER-positive breast cancer: A review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncology Reviews, 19, 1564642. https://doi.org/10.3389/or.2025.1564642
- Liu, Y. (2025). Recent advances and updated highlights in breast cancer pathologic diagnosis: A narrative review. Translational Breast Cancer Research, 6, 3. https://doi.org/10.21037/tbcr-24-27
- FB (Forward/Backward Searched Articles)
- Agelidis, A., Ter-Zakarian, A., & Jaloudi, M. (2025). Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond. Breast Cancer : Targets and Therapy, 17, 523. https://doi.org/10.2147/BCTT.S516125
- Oey, O., Wijaya, W., & Redfern, A. (2024). Eribulin in breast cancer: Current insights and therapeutic perspectives. World Journal of Experimental Medicine, 14(2), 92558. https://doi.org/10.5493/wjem.v14.i2.92558
- Smith, A. E. (2024). An update on metastatic breast cancer – new targeted therapies. Medicine Today, 25(8), 77-84. https://medicinetoday.com.au/mt/2024/august/regular-series/update-metastatic-breast-cancer-new-targeted-therapies
- Nickson, C., Mason, K. E., English, D. R., & Kavanagh, A. M. (2025). Risk-adjusted breast screening: an Australian perspective on the ROSA project. The Lancet Regional Health – Western Pacific, 46, Article 100057. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065%2825%2900057-4/fulltext
- Baum, S. (2023). Exploring Disparities in Breast Cancer Screening: An Ecological Analysis of Australian Data. Asian Pacific Journal of Cancer Prevention : APJCP, 24(12), 4139. https://doi.org/10.31557/APJCP.2023.24.12.4139
- Foidart, P., et al. (2025). Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer? Insights from the OlympiA trial. Annals of Oncology, 36(5), 499-507. https://gs.amegroups.org/article/view/134987/html?utm_source
- Zettler, C. M., et al. (2024). Cost-effectiveness of adjuvant olaparib for patients with high-risk, early-stage breast cancer and a germline BRCA1/2 mutation. JAMA Network Open, 7(3), e2413458. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813458?utm_source
- Yong, C. H., Gupta, A., & Joshi, R. (2022). CSCO breast cancer management guidelines 2022: Australian perspective. Translational Breast Cancer Research, 3, 36. https://doi.org/10.21037/tbcr-22-46
- Mazza, D., et al. (2025). The early detection of breast cancer: an update for Australian general practitioners. Australian Journal of General Practice, 54(5), 287-294. https://www1.racgp.org.au/ajgp/2025/may/the-early-detection-of-breast-cancer-an-update-fro
- DB (Database)
- The Cancer Genome Atlas (TCGA) Research Network. TCGA-BRCA: Breast Invasive Carcinoma dataset. National Cancer Institute. https://portal.gdc.cancer.gov/projects/TCGA-BRCA
- MT (Medicine/Treatment Articles)
- Geyer, C. E., Jr., et al. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib for gBRCA1/2-associated early breast cancer. The New England Journal of Medicine, 386(8), 2393-2404. https://pubmed.ncbi.nlm.nih.gov/36228963/
- Abraham, J. E., et al. (2025). Neoadjuvant PARP inhibitor scheduling with olaparib and chemotherapy in the PARTNER trial of early-stage gBRCA-mutated triple-negative breast cancer. Nature Communications, 16, Article 2754. https://doi.org/10.1038/s41467-025-59151-0
